Shattuck Labs, Inc., a clinical-stage biotechnology company, has filed a prospectus detailing the resale of 3,100,823 shares of common stock by its selling stockholders. These shares are issuable upon the exercise of pre-funded warrants acquired under a securities purchase agreement dated December 21, 2023. The company, which is listed on The Nasdaq Global Select Market under the symbol 'STTK', will not receive proceeds from the stockholders' sales but will receive a nominal cash exercise price upon any exercise of the warrants for cash. The proceeds are intended for general corporate purposes. The selling stockholders may sell the shares at varying prices and are responsible for any associated selling expenses. The prospectus, dated January 31, 2024, also includes risk factors and a plan of distribution for the shares. Shattuck Labs emphasizes that the registration of the shares does not guarantee that the stockholders will sell any or all of the shares.

Shattuck Labs, Inc., a clinical-stage biotechnology company, has filed a prospectus detailing the resale of 3,100,823 shares of common stock by its selling stockholders. These shares are issuable upon the exercise of pre-funded warrants acquired under a securities purchase agreement dated December 21, 2023. The company, which is listed on The Nasdaq Global Select Market under the symbol 'STTK', will not receive proceeds from the stockholders' sales but will receive a nominal cash exercise price upon any exercise of the warrants for cash. The proceeds are intended for general corporate purposes. The selling stockholders may sell the shares at varying prices and are responsible for any associated selling expenses. The prospectus, dated January 31, 2024, also includes risk factors and a plan of distribution for the shares. Shattuck Labs emphasizes that the registration of the shares does not guarantee that the stockholders will sell any or all of the shares.